Since the late 1990s, major efforts have been made to discover small molecules directed against either the absent or dysfunctional chloride channel in epithelial membranes, leading to the introduction of CFTR modulators, a new category of therapeutic agents designed to target the molecular defects of CF. Here, CFTR is linked to cystic fibrosis.